[go: up one dir, main page]

CR20130106A - Nuevos moduladores de trpv3 - Google Patents

Nuevos moduladores de trpv3

Info

Publication number
CR20130106A
CR20130106A CR20130106A CR20130106A CR20130106A CR 20130106 A CR20130106 A CR 20130106A CR 20130106 A CR20130106 A CR 20130106A CR 20130106 A CR20130106 A CR 20130106A CR 20130106 A CR20130106 A CR 20130106A
Authority
CR
Costa Rica
Prior art keywords
new
trpv3 modulators
trpv3
modulators
compositions
Prior art date
Application number
CR20130106A
Other languages
English (en)
Inventor
Erol K Bayburt
Bruce Clapham
Phil B Cox
Jerome F Daanen
Arthur Gomtsyan
Michael E Kort
Philip R Kym
Eric A Voight
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20130106A publication Critical patent/CR20130106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Moduladores de TRPV3 de fórmula (I) (I),donde G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, y p son como se definen en la memoria descriptiva. Composiciones que comprenden dichos compuestos y métodos para tratar estados clínicos y trastornos usando dichos compuestos y composiciones.
CR20130106A 2010-08-10 2013-03-11 Nuevos moduladores de trpv3 CR20130106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/001213 WO2012019315A1 (en) 2010-08-10 2010-08-10 Novel trpv3 modulators

Publications (1)

Publication Number Publication Date
CR20130106A true CR20130106A (es) 2013-07-19

Family

ID=45567252

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130106A CR20130106A (es) 2010-08-10 2013-03-11 Nuevos moduladores de trpv3

Country Status (14)

Country Link
US (1) US9156788B2 (es)
EP (1) EP2603490A4 (es)
JP (1) JP2013538800A (es)
KR (1) KR20130097748A (es)
CN (1) CN103140476A (es)
AU (1) AU2010359001A1 (es)
BR (1) BR112013003121A2 (es)
CA (1) CA2807538A1 (es)
CR (1) CR20130106A (es)
MX (1) MX2013001612A (es)
PH (1) PH12013500275A1 (es)
RU (1) RU2013110324A (es)
SG (1) SG187811A1 (es)
WO (1) WO2012019315A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013001612A (es) 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
WO2012100153A1 (en) * 2011-01-20 2012-07-26 Northeastern University Real-time pavement profile sensing system using air-coupled surface wave
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
JP2014530911A (ja) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Ｔｒｐｖ３モジュレーターとしてのメタノール誘導体
CN104254522A (zh) * 2011-10-24 2014-12-31 艾伯维公司 作为trpv3调节剂的甲醇衍生物
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN109942459B (zh) * 2017-12-21 2022-06-24 南京理工大学 一种合成3-二氟甲基-3-丙烯腈类化合物的方法
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138547A (en) * 1978-04-14 1979-10-27 Takeda Chem Ind Ltd Beta-aminoketone derivative and its preparation
JPS60109539A (ja) * 1983-11-15 1985-06-15 Sumitomo Chem Co Ltd ベンジルアルコ−ル誘導体
JPS60230742A (ja) * 1984-04-28 1985-11-16 Shinko Electric Co Ltd ル−プ式デ−タ伝送方式における割込み信号伝送方法
JPS6471830A (en) * 1987-09-11 1989-03-16 Rikagaku Kenkyusho Monofluorocyclobutanes and production thereof
DE3914820A1 (de) * 1989-05-05 1990-11-08 Basf Ag Neue pyridinderivate und ihre verwendung als fungizide
DE4018260A1 (de) * 1990-06-07 1991-12-12 Basf Ag Derivate des (beta)-picolins und diese enthaltende pflanzenschutzmittel
DE4318916A1 (de) 1993-06-07 1994-12-08 Bayer Ag Cyclobutylazole
GB9315808D0 (en) * 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1215715A (zh) * 1997-10-28 1999-05-05 兰州大学 立体选择性1,3－二醇合成方法
AU2720199A (en) * 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2002022572A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
EP1399558A2 (en) 2001-06-13 2004-03-24 Novartis AG Vanilloid receptor-related nucleic acids and polypeptides
CA2481320A1 (en) * 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
NZ540328A (en) 2002-11-06 2008-02-29 Amgen Inc Fused heterocyclic compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7803790B2 (en) * 2005-05-09 2010-09-28 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CN101355946B (zh) 2005-11-04 2013-05-08 海德拉生物科学公司 调节trpv3功能的化合物
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
ATE522519T1 (de) * 2008-03-20 2011-09-15 Hoffmann La Roche Pyrrolidinylderivate und anwendungen davon
GEP20125709B (en) * 2008-06-17 2012-12-10 Glenmark Pharmaceuticals Sa Chromane derivatives as trpv3 modulators
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
JP5697163B2 (ja) * 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
KR101469395B1 (ko) * 2010-07-12 2014-12-04 에프. 호프만-라 로슈 아게 1-하이드록시이미노-3-페닐-프로판
MX2013001612A (es) 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
JP2014530911A (ja) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Ｔｒｐｖ３モジュレーターとしてのメタノール誘導体

Also Published As

Publication number Publication date
US20130150409A1 (en) 2013-06-13
KR20130097748A (ko) 2013-09-03
CA2807538A1 (en) 2012-02-16
EP2603490A4 (en) 2014-01-01
EP2603490A1 (en) 2013-06-19
RU2013110324A (ru) 2014-09-20
AU2010359001A1 (en) 2013-03-14
SG187811A1 (en) 2013-03-28
WO2012019315A1 (en) 2012-02-16
BR112013003121A2 (pt) 2016-06-28
PH12013500275A1 (en) 2017-08-23
US9156788B2 (en) 2015-10-13
MX2013001612A (es) 2013-07-05
CN103140476A (zh) 2013-06-05
JP2013538800A (ja) 2013-10-17

Similar Documents

Publication Publication Date Title
CR20130106A (es) Nuevos moduladores de trpv3
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
ECSP088961A (es) Nuevos herbicidas
SV2009003300A (es) Nuevos herbicidas
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
UY33735A (es) Compuestos antivirales
CR20150217A (es) Inhibidores de histona demetilasas
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
CO6690755A2 (es) Heteroarilos como inhibidores de p13k
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
ECSP11011245A (es) Novedosos herbicidas
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
EA201400339A1 (ru) Новые имидазоламины в качестве модуляторов киназной активности
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
MX2015003701A (es) Composiciones para tratamiento.